S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:RUBY

Rubius Therapeutics Competitors

$9.48
-0.21 (-2.17 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.19
Now: $9.48
$9.80
50-Day Range
$6.27
MA: $7.75
$9.69
52-Week Range
$3.35
Now: $9.48
$13.70
Volume603,340 shs
Average Volume423,424 shs
Market Capitalization$767.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.99

Competitors

Rubius Therapeutics (NASDAQ:RUBY) Vs. RVMD, SRNE, SGMO, REPL, SRRK, and NK

Should you be buying RUBY stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Rubius Therapeutics, including Revolution Medicines (RVMD), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Replimune Group (REPL), Scholar Rock (SRRK), and NantKwest (NK).

Revolution Medicines (NASDAQ:RVMD) and Rubius Therapeutics (NASDAQ:RUBY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Revolution Medicines and Rubius Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Rubius Therapeutics03202.40

Revolution Medicines presently has a consensus target price of $43.75, suggesting a potential upside of 7.31%. Rubius Therapeutics has a consensus target price of $11.40, suggesting a potential upside of 20.25%. Given Rubius Therapeutics' higher probable upside, analysts clearly believe Rubius Therapeutics is more favorable than Revolution Medicines.

Insider and Institutional Ownership

71.6% of Revolution Medicines shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 58.4% of Rubius Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Revolution Medicines and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution MedicinesN/AN/AN/A
Rubius TherapeuticsN/A-69.59%-46.80%

Valuation & Earnings

This table compares Revolution Medicines and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million54.08$-47,660,000.00N/AN/A
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-4.56

Revolution Medicines has higher revenue and earnings than Rubius Therapeutics.

Summary

Revolution Medicines beats Rubius Therapeutics on 6 of the 9 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Rubius Therapeutics (NASDAQ:RUBY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sorrento Therapeutics and Rubius Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00203.00
Rubius Therapeutics03202.40

Sorrento Therapeutics presently has a consensus target price of $27.00, suggesting a potential upside of 184.21%. Rubius Therapeutics has a consensus target price of $11.40, suggesting a potential upside of 20.25%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sorrento Therapeutics is more favorable than Rubius Therapeutics.

Insider and Institutional Ownership

24.1% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 58.4% of Rubius Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sorrento Therapeutics and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-760.19%-490.67%-38.31%
Rubius TherapeuticsN/A-69.59%-46.80%

Volatility and Risk

Sorrento Therapeutics has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sorrento Therapeutics and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million79.48$-292,070,000.00($2.12)-4.48
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-4.56

Rubius Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Rubius Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Rubius Therapeutics beats Sorrento Therapeutics on 7 of the 12 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Rubius Therapeutics (NASDAQ:RUBY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Sangamo Therapeutics and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million21.75$-95,190,000.00($0.85)-18.53
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-4.56

Sangamo Therapeutics has higher revenue and earnings than Rubius Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sangamo Therapeutics and Rubius Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02302.60
Rubius Therapeutics03202.40

Sangamo Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 14.29%. Rubius Therapeutics has a consensus target price of $11.40, suggesting a potential upside of 20.25%. Given Rubius Therapeutics' higher probable upside, analysts clearly believe Rubius Therapeutics is more favorable than Sangamo Therapeutics.

Insider and Institutional Ownership

54.5% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 1.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 58.4% of Rubius Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sangamo Therapeutics and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-91.17%-23.12%-14.74%
Rubius TherapeuticsN/A-69.59%-46.80%

Volatility and Risk

Sangamo Therapeutics has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.

Summary

Sangamo Therapeutics beats Rubius Therapeutics on 8 of the 13 factors compared between the two stocks.

Replimune Group (NASDAQ:REPL) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Replimune Group and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A$-52,630,000.00($1.54)-28.07
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-4.56

Replimune Group is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Replimune Group and Rubius Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Replimune Group00903.00
Rubius Therapeutics03202.40

Replimune Group presently has a consensus target price of $54.25, suggesting a potential upside of 25.49%. Rubius Therapeutics has a consensus target price of $11.40, suggesting a potential upside of 20.25%. Given Replimune Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Replimune Group is more favorable than Rubius Therapeutics.

Insider & Institutional Ownership

60.9% of Replimune Group shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 50.9% of Replimune Group shares are held by insiders. Comparatively, 58.4% of Rubius Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Replimune Group and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Replimune GroupN/A-31.09%-25.11%
Rubius TherapeuticsN/A-69.59%-46.80%

Risk & Volatility

Replimune Group has a beta of 3.23, indicating that its share price is 223% more volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.

Summary

Replimune Group beats Rubius Therapeutics on 8 of the 11 factors compared between the two stocks.

Scholar Rock (NASDAQ:SRRK) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Scholar Rock and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$20.49 million94.28$-51,000,000.00($1.85)-31.04
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-4.56

Scholar Rock has higher revenue and earnings than Rubius Therapeutics. Scholar Rock is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Scholar Rock and Rubius Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Scholar Rock00503.00
Rubius Therapeutics03202.40

Scholar Rock presently has a consensus target price of $52.40, suggesting a potential downside of 8.76%. Rubius Therapeutics has a consensus target price of $11.40, suggesting a potential upside of 20.25%. Given Rubius Therapeutics' higher probable upside, analysts plainly believe Rubius Therapeutics is more favorable than Scholar Rock.

Insider & Institutional Ownership

66.3% of Scholar Rock shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 24.6% of Scholar Rock shares are held by insiders. Comparatively, 58.4% of Rubius Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Scholar Rock and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Scholar Rock-301.13%-61.68%-35.74%
Rubius TherapeuticsN/A-69.59%-46.80%

Risk & Volatility

Scholar Rock has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.

Summary

Scholar Rock beats Rubius Therapeutics on 7 of the 13 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares NantKwest and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0046,830.73$-65,790,000.00($0.70)-24.64
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-4.56

NantKwest has higher revenue and earnings than Rubius Therapeutics. NantKwest is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for NantKwest and Rubius Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Rubius Therapeutics03202.40

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 4.35%. Rubius Therapeutics has a consensus target price of $11.40, suggesting a potential upside of 20.25%. Given Rubius Therapeutics' higher probable upside, analysts plainly believe Rubius Therapeutics is more favorable than NantKwest.

Insider & Institutional Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 72.1% of NantKwest shares are held by insiders. Comparatively, 58.4% of Rubius Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares NantKwest and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Rubius TherapeuticsN/A-69.59%-46.80%

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.

Summary

NantKwest beats Rubius Therapeutics on 7 of the 13 factors compared between the two stocks.


Rubius Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RVMD
Revolution Medicines
1.4$40.77-1.8%$2.71 billion$50.04 million0.00Analyst Downgrade
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$9.50-15.9%$2.50 billion$31.43 million-5.83High Trading Volume
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$15.75-2.8%$2.23 billion$102.43 million-18.98
Replimune Group logo
REPL
Replimune Group
1.5$43.23-5.4%$1.99 billionN/A-26.04Increase in Short Interest
Heavy News Reporting
Scholar Rock logo
SRRK
Scholar Rock
1.3$57.43-1.1%$1.93 billion$20.49 million-26.47Increase in Short Interest
NantKwest logo
NK
NantKwest
1.1$17.25-3.1%$1.87 billion$40,000.00-24.30Analyst Upgrade
Insider Selling
REGENXBIO logo
RGNX
REGENXBIO
1.5$48.34-3.3%$1.81 billion$35.23 million-13.24Insider Selling
Vericel logo
VCEL
Vericel
1.2$39.01-1.3%$1.77 billion$117.85 million-3,901.00Analyst Report
Analyst Revision
TBIO
Translate Bio
1.4$23.33-0.1%$1.73 billion$7.80 million-13.64
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$8.80-2.4%$1.55 billion$48.83 million-11.58Analyst Upgrade
Heavy News Reporting
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$18.61-1.3%$1.45 billionN/A-4.03
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$67.85-2.2%$1.34 billionN/A-45.84Analyst Upgrade
High Trading Volume
ALEC
Alector
1.3$16.87-7.9%$1.34 billion$21.22 million-7.56Analyst Report
Heavy News Reporting
Cellectis logo
CLLS
Cellectis
0.8$30.91-0.1%$1.31 billion$22.99 million-16.44
PCVX
Vaxcyte
1.8$25.70-0.5%$1.31 billionN/A0.00Analyst Downgrade
Insider Selling
Heavy News Reporting
PASG
Passage Bio
1.3$28.24-5.6%$1.29 billionN/A0.00
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$17.73-1.5%$1.28 billion$356.07 million8.69Heavy News Reporting
Mesoblast logo
MESO
Mesoblast
1.4$9.72-1.1%$1.14 billion$32.16 million-11.05
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$11.37-5.2%$1.11 billion$250,000.00-8.95Analyst Downgrade
TCRR
TCR2 Therapeutics
1.2$32.80-3.3%$1.10 billionN/A-13.44Analyst Downgrade
Sutro Biopharma logo
STRO
Sutro Biopharma
1.1$27.03-4.1%$1.04 billion$42.74 million-24.57Decrease in Short Interest
BDTX
Black Diamond Therapeutics
1.6$26.94-6.2%$969.73 millionN/A-4.45Insider Selling
Heavy News Reporting
CRTX
Cortexyme
1.3$32.61-2.1%$961.93 millionN/A-13.59Analyst Upgrade
Compugen logo
CGEN
Compugen
1.4$13.01-3.8%$890.14 million$17.80 million-35.16Increase in Short Interest
Heavy News Reporting
ATHA
Athira Pharma
1.8$26.55-0.9%$862.48 millionN/A0.00Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$7.18-2.2%$785.99 million$9.86 million-12.17
PRVL
Prevail Therapeutics
1.4$22.93-0.1%$785.26 millionN/A-9.68Decrease in Short Interest
Curis logo
CRIS
Curis
0.9$12.80-7.9%$752.86 million$10 million-15.61Analyst Upgrade
Heavy News Reporting
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.72-6.6%$744.22 million$1.12 million-5.78
ORTX
Orchard Therapeutics
1.6$7.08-1.0%$688.63 million$2.51 million-3.87Analyst Revision
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$13.95-1.1%$653.07 million$69.89 million-3.33
Agenus logo
AGEN
Agenus
1.6$3.35-2.1%$637.00 million$150.05 million-3.07Analyst Report
Heavy News Reporting
MeiraGTx logo
MGTX
MeiraGTx
1.4$16.36-0.4%$628.42 million$13.29 million-11.60
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.66-33.9%$621.80 million$14.75 million-2.43Analyst Report
High Trading Volume
Increase in Short Interest
Heavy News Reporting
HARP
Harpoon Therapeutics
1.5$23.40-8.7%$593.89 million$5.78 million-10.99Unusual Options Activity
Heavy News Reporting
DTIL
Precision BioSciences
1.5$11.30-8.1%$593.02 million$22.24 million-5.62High Trading Volume
Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$14.39-3.8%$524.53 millionN/A-4.36Analyst Downgrade
High Trading Volume
Heavy News Reporting
Surface Oncology logo
SURF
Surface Oncology
0.9$12.30-2.8%$500.33 million$15.36 million-13.98Increase in Short Interest
Heavy News Reporting
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$9.02-1.0%$471.30 million$2.91 million-3.14
OYST
Oyster Point Pharma
1.7$17.92-3.5%$463.56 millionN/A-1.64
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$19.41-3.8%$430.49 millionN/A-16.88
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$3.39-1.8%$420.17 million$4.13 million-7.53
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$6.48-0.3%$391.71 millionN/A-2.83Analyst Upgrade
Decrease in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.40-0.2%$390.90 millionN/A-6.88Analyst Downgrade
Increase in Short Interest
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.12-14.9%$363.44 million$147.87 million-3.03High Trading Volume
Heavy News Reporting
OCGN
Ocugen
1.1$2.22-1.8%$359.70 millionN/A-1.50Increase in Short Interest
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$11.02-7.6%$358.50 millionN/A-4.53Decrease in Short Interest
IPHA
Innate Pharma
1.1$4.52-1.5%$356.99 million$96.12 million-13.29Increase in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$18.11-1.3%$352.75 million$340,000.00-6.40Decrease in Short Interest
INMB
INmune Bio
1.1$24.82-0.4%$333.78 millionN/A-25.59
This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.